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Abstract
Background—Changes in the epidemiology of end stage liver disease may lead to increased risk 
of dropout from the liver transplant waitlist. Anticipating the future of liver transplant waitlist 
characteristics is vital when considering organ allocation policy.
Methods—We performed a discrete event simulation to forecast patient characteristics and rate 
of waitlist dropout. Estimates were simulated from 2015–2025. The model was informed by data 
from the Organ Procurement and Transplant Network, 2003–2014. National data are estimated 
along with forecasts for 2 regions.
Results—NASH will increase from 18% of waitlist additions to 22% by 2025. Hepatitis C will 
fall from 30% to 21%. Listings over age 60 will increase from 36% to 48%. The hazard of dropout 
will increase from 41% to 46% nationally. Wait times for transplant for patients listed with a 
MELD between 22 and 27 will double. Region 5, which transplants at relatively higher MELD 
scores, will experience an increase from 53% to 64% waitlist dropout. Region 11, which 
transplants at lower MELD scores, will have an increase in waitlist dropout from 30% to 44%.
Conclusions—The liver transplant waitlist size will remain static over the next decade due to 
patient dropout. Liver transplant candidates will be older, more likely to have NASH and will wait 
for transplantation longer even when listed at a competitive MELD score. There will continue to 
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be significant heterogeneity among transplant regions where some patients will be more likely to 
drop out of the waitlist than receive a transplant.
Introduction
With the advent of highly effective medications for hepatitis C (HCV) and the ongoing 
epidemic of nonalcoholic fatty liver disease (NAFLD), the main etiology of end stage liver 
disease (ESLD) and liver transplantation (LT) will change over the next 2 decades.(1, 2) 
Implementation of birth-cohort screening for HCV and new medications with sustained 
virologic response rates >90% may render HCV an uncommon disease in the future.(1) 
Continued increases in diabetes and obesity will increase the incidence of NAFLD, and as 
the NAFLD population ages, many will develop cirrhosis and ESLD. The changing etiology 
of ESLD may impact the utility of listing patients for LT as older patients with multiple 
comorbidities may be more likely to die or be removed from the wait list than receive a 
transplant.(3, 4)
Already, the transplant community has seen stagnation if not slight decline in the numbers of 
deceased donor liver transplants performed nationally since 2006. Much of this decline is 
due to donor graft quality and donation after cardiac death (DCD) procurement strategies.(5) 
Transplant centers are less likely to use livers from donors with significant steatosis, 
advancing age, obesity, and DCD, even when they can transplant the donor’s other organs.
(5) The recent decline in LT may be a harbinger of further reductions in LT in the coming 
years.(6) Such a decline in transplant availability would place a greater burden on centers 
managing ESLD patients on the waitlist.
Patient characteristics on the liver transplant waitlist have changed over the past decade and 
these attributes vary considerably by region.(4) In order to anticipate potential changes to 
waitlist attributes, we aimed to determine future demographic characteristics of the LT 
waiting list and determine the rate of waitlist removal and receipt of liver transplantation 
through discrete event simulation (DES). We performed our analyses using both national 
United Network of Organ Sharing (UNOS) data and data from 2 disparate regions to 
demonstrate the heterogeneity among UNOS regions.
Materials and Methods
Overview
We used the Standard Transplant Analysis and Research (STAR) dataset files from the 
Organ Procurement and Transplant Network (OPTN), a.k.a. the ‘UNOS database’ to create a 
DES model to predict patient characteristics and waitlist times on the liver transplant waitlist 
on a national level and for 2 selected UNOS regions. The DES model was informed by data 
from 2003–2012.(4) Data from 2013–2014 were withheld for validation of the model. We 
previously used this database to study the clinical and demographic attributes of the patient 
population on the waiting list (ie, describe demographic trends (gender, age, race) and other 
clinical attribute trends (model for end stage liver disease-MELD score, disease type, etc.)).
(4) The current study focused on using a DES model to estimate waitlist times dynamically 
into the future while considering the changes in demographic and clinical attributes over 
Yi et al. Page 2
Transplantation. Author manuscript; available in PMC 2018 October 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
time as well as liver availability. Each patient’s length of stay on the waitlist is controlled by 
his/her assigned “waiting time”, which is estimated by competing risk analysis. This is also 
used to determine their outcome ie, transplant versus drop out. Drop out is defined as 
removal from the list for any reason except transplant. While most dropouts occur because 
patients die or become too sick to transplant, a few (3.58% of waitlist additions nationally 
from 2003–2014)(4) occur due to ‘condition improved’. In this analysis, we include these 
patients because (i) 1 of our goals is to estimate waitlist size and these patients contribute to 
that; (ii) the number of these “good” dropouts is small in comparison and has been 
decreasing over time(4) and is expected to continue to do so.
Inclusion/Exclusion criteria
Inclusion and exclusion criteria for the simulation model are similar to the previously 
reported retrospective analysis.(4) Briefly, data from patients who received living donors and 
partial liver transplant were excluded. Pediatric patients under age 18 years of age were 
excluded. Acute liver failure (Status 1) patients were excluded. Data prior to the MELD era 
(February 2002) were excluded. We judged each of these groups to be systematically 
different than the clear majority of adults with ESLD awaiting an orthotopic liver transplant.
Setting
We studied the waitlist at the national level and specifically looked at region 5 and region 11. 
Region 5 includes Arizona, California, Nevada, New Mexico and Utah. It is 1 of the 
geographically largest and most populous transplant regions in US and transplants at very 
high MELD scores; we believe these data are representative of the high MELD regions. 
Region 11 includes North Carolina, Kentucky, South Carolina, Tennessee and Virginia. In 
contrast to region 5, region 11 is representative of smaller regions that can transplant at 
relatively lower MELD scores.
Variables
Initial MELD score—Initial MELD score is the first MELD score recorded when a patient 
joins the list. The score ranges from 6 to 40, and was categorized in quartiles based on 
clinical factors (6–15, 16–21, 22–27, 28–40). 22 and 28 were common levels for 
hepatocellular carcinoma exception points until October 2015 (patients now get 28 points 
after a 6-month waiting period).
Disease etiology
In the UNOS database, there are 2 variables for diagnosis: “primary diagnosis” and 
“secondary diagnosis”. The 2 variables have 79 different descriptions for the disease. We 
grouped them into 6 categories: hepatitis B (HBV), hepatitis C (HCV), nonalcoholic 
steatohepatitis (NASH), Alcoholic Cirrhosis, hepatocellular carcinoma (HCC) and other. 
The HCV group is inclusive of HCV plus alcohol. In the analysis, HCC became the primary 
diagnosis if it was listed as first or second due to the MELD exception point advantage it 
confers.
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Construction of the Simulation Model
Hypothetical patient demographic (gender, age, race) and clinical characteristics (ESLD 
etiology and MELD score at list entry) are assigned probabilistically, per the flow chart in 
Figure 1. Statistical models, based on retrospective UNOS data analysis(4), predict whether 
individual patients with certain characteristics are likely to drop off the waitlist or receive 
transplant. A corresponding waiting time is assigned to the patients based on probabilistic 
analysis of historic wait times for patients with similar attributes. Once a patient has waited 
in the queue until his or her preassigned transplant time (ie, he/she is the next to receive 
transplant offer), the simulation determines the probability of liver availability based on 
historic trends. If a liver is available, the patient receives a transplant. If a liver is not 
available, the simulation proceeds until the next available liver appears. During this time, 
competing risk analysis determined if the listed patent can wait for the next available graft, 
or if the patient drops out from the waitlist. For example, a patient joins the list on day 1. 
The patient is probabilistically determined to move towards the top of the waitlist, and may 
be assigned a waiting time of 100 days. If no liver is available on the 100th day, he waits 
until the preassigned drop out time: hypothetically, the 120th day. During those 20 days, 
patient has priority to receive any new available liver. If no new liver is available, the patient 
drops out. The model was implemented using the software Arena version 15 (Rockwell 
Automation). The simulation model runs retrospectively from 2003–2014 and prospectively 
from 2015–2025 and is performed by running 5 replications; this number of replications 
allowed a 95% confidence interval half-width of 1% or less around the mean.
Waitlist additions arrival and liver graft availability
For the waitlist additions and liver graft availability from 2003–2014, we used historical 
values. We proposed several possible trends for patient arrival and liver availability after 
2014 which are based on a range of possible scenarios (see below). In the simulation model, 
patients are listed per a constant daily rate which is calculated by dividing the historical 
number of patient arrivals in that year by 365. Like patient arrivals, the total available livers 
in each year are distributed daily in the simulation system ie, livers arrive to the system per a 
constant daily rate which may vary in different years.
Model Validation
The simulation model was constructed using data from 2003–2012. Data from 2013–14 
were withheld for validation. Actual and simulated national and regional values from 2014 
are shown in Table 1. Retrospective model outputs are also compared to historical data in 
Figure 2
Scenario analyses
We considered 3 simulation scenarios acknowledging that there may be unanticipated events 
that impact the available numbers of grafts for liver transplantation, the volume of new 
arrivals on the transplant waitlist and the health and demographic characteristics of patients 
on the waitlist. Several scenarios were defined and analyzed (Table 2). Each scenario is 
composed of 3 parts: A: liver graft availability after 2014; B: Waitlist additions after 2014; 
C: Patients’ demographic and clinical trends after 2014. For each part, subscenarios are 
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designed based on plausible trends (5–7). Liver graft availability may potentially increase as 
an unexpected consequence of the opioid epidemic impacting parts of the United States. 
Waitlist additions may change pending the success (or failure) of pharmacotherapy for 
NAFLD. Finally, patient clinical attributes may change via UNOS policy (HCC exception 
points), shifts in disease epidemiology (NAFLD replacing HCV) or patient demographics. 
By combining different possibilities from each of the 3 pieces, 3 scenarios are constructed: 
baseline, optimistic, and pessimistic scenarios.
Results
National waitlist
In our baseline scenario, the size of the national liver transplant waitlist will change from 13 
950 in 2015 to 17 355 in 2025, a 24% increase. Nationally, the rate of wait list drop out will 
increase from 41.3% to 45.8% (Table 3). Patients on the waitlist will be older; the proportion 
older than 60 will increase from 35.9% to 47.1%. HCC will be the leading indication for 
liver transplantation, increasing from 16.5% to 28.5% and NASH will overtake HCV as the 
leading etiology of liver disease for new arrivals on the waitlist, increasing from 18.2% to 
21.9%. We estimate that a patient listed in 2015 with a MELD score between 22 and 27 
waited on average 82 days for a liver transplant. This time will increase to 123 days in 2020 
and to 182 days in 2025.
Under optimistic conditions (an increase in liver availability with unchanged waitlist 
additions and patient characteristics), the waitlist drop out will decrease from 39.3% to 
28.7% by 2025. Accordingly, expected wait time for a patient entering the waitlist with a 
MELD score between 22 and 27 would fall from 88 days to 62 days.
Under pessimistic conditions (a decrease in liver graft availability, an increase in patients 
added to the waitlist and further changes in patient attributes), the dropout rate would 
increase from 44.9% to 69.9 % by 2025. Wait times for a patient entering the waitlist with a 
MELD score between 22 and 27 would increase from 96 days to 368 days by 2025. Selected 
characteristics of the national waitlist for the baseline, optimistic and pessimistic scenarios 
are shown in Table 3 and Figure 2a.
Regions 5 and 11
Regional waitlists will have considerable variability. In the baseline scenario, the region 5 
waitlist size will change from 2681 in 2015 to 3107 in 2025, a 15.9% increase. The rate of 
drop out will change from 52.9% to 63.7%. Patients listed at a MELD score between 22 and 
27 will have an increase in wait time from 110 days to 191 days by 2025. In comparison, the 
region 11 waitlist will change from 706 patients in 2015 to 863 patients in 2025, a 22.2% 
increase. The rate of dropout will change from 30.3% to 43.9%. Wait times in region 11 will 
increase from 48 days to 82 days by 2025. The region 5 waitlist will have a greater 
proportion of HCV and HCC while NASH will be more common in region 11. Patients in 
region 5 will be older at the time of listing with a higher proportion over age 60 compared to 
region 11. Selected characteristics of the region 5 and 11 waitlists for the neutral, optimistic 
and pessimistic scenarios are shown in Table 4 and Figure 2b.
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Discussion
This is the first detailed simulation that seeks to estimate future demographic and clinical 
attributes of patients on the liver transplant waitlist. Additionally, we estimate waitlist times 
and probability of waitlist drop out. Such modeling endeavors are critically important as we 
anticipate potential changes in UNOS region realignment and organ allocation as well as 
adjust to the reality of changing epidemiology of cirrhosis and end stage liver disease. We 
anticipate that there will be continued upward pressure on MELD scores for liver transplant 
listing, resulting in longer waitlist times and greater risk of waitlist dropout. These events 
may have a multifaceted impact on the transplant community.
Our simulation showed that the liver transplant waitlist size will remain relatively static on a 
national level over the next decade even as waitlist additions increase by 24%. This balance 
will not be achieved by additional transplants, but by increased waitlist drop out instead. The 
probability of drop out will exceed that of transplant under some scenarios and in regions 
that transplant at higher MELD scores. HCC will be the leading indication for liver 
transplant and NASH will overtake HCV as the leading etiology of cirrhosis. Liver 
transplant candidates will be older, with a growing proportion over the age of 60. Patients 
listed with MELD scores in the 22–27 range will wait for transplantation longer; some for 
greater than a year. There will continue to be significant heterogeneity among transplant 
regions where some patients will be more likely to drop out from the waitlist than receive a 
transplant. This phenomenon, already occurring in some regions, will become more 
common over time.
Quantification of these future trends will be important in informing public health policy. 
Important decisions looming for the transplant community include redrawing UNOS regions 
to lessen the effect of geographic location on access to organs. Accurate forecasting of future 
waitlist times and the economic impact of rezoning UNOS regions and donor service areas 
will be vital to crafting new policy. While rezoning the UNOS regions will not change the 
net number of livers available for transplant, waitlist times may change, thus anticipating 
future waitlist times will be integral. Such rezoning is controversial and focused primarily on 
equitable allocation of organs in the near (<5 years) term. There has been less emphasis on 
long term (~10 years) forecasting. To create an equitable strategy for organ allocation long 
term, multiple complex interactions must be considered with accurate forecasts of the 
changing transplant candidate and organ donor demographics.
Worsening organ shortages have already reignited a push for uniformly higher donation rates 
across the U.S. As patients get sicker on the waitlist, risk tolerance for marginal liver grafts 
may change. Communicating these risks to patients, payers, and the public will be vital to 
avoid unintended side effects of policy changes such as those made by CMS in 2007. 
Outcomes-based auditing likely altered waitlist management and clinical decision making 
leading to delisting of many patients who may have otherwise benefitted from transplant.(8) 
A future where patients are older and sicker on the transplant waitlist might exacerbate 
transplant centers’ perceptions of risk.
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As patients wait longer for transplant, expensive complications will become more common. 
These issues have been raised previously,(6) but deserve updated emphasis as healthcare 
costs continue to spiral upwards. For example, complicated variceal bleeding may increase, 
which would lead to high hospitalization costs of $28 513 per patient in 2015 US dollars 
(adjusted for inflation from 2008 US dollars using the Consumer Price Index Medical Care 
component for all US cities).(6, 9, 10) From 2005 to 2009, inpatient charges for hepatic 
encephalopathy rose from $4.7 billion to $7.2 billion.(6, 11) Additionally, hospital 
readmission is often part of the dying process for a patient with ESLD, ultimately destined 
to drop off the list. In a single center study of 402 patients discharged after a complication of 
cirrhosis, 69% had at least 1 nonelective readmission. Additional costs for those 
readmissions ranged from $20 581 to $29 898 per patient.(12)
The increased cost and risk of worse outcome due to these trends in listed patients will also 
adversely affect posttransplant outcomes. Increased age at transplant is associated with worst 
posttransplant survival.(3) Such posttransplant effects will be compounded by decline in 
graft quality.(6) Sicker transplant recipients combined with marginal donors increase 
transplant related costs.(13) Donors in the highest risk quartile of the Donor Risk Index add 
$14 750 to the cost of transplant and another $27 000 to post transplant hospitalization, 
relative to low risk donors, pushing overall 1 year costs to approximately $250 000 in 
inflation adjusted 2015 U.S. dollars. DCD donors increased costs by $26 000 over standard 
donation after brain death (DBD) donors in adjusted 2015 dollars.(6, 10, 13) These costs are 
due to longer hospitalizations associated with higher risk donors. (6, 14)
Any forecasting model is subject to certain limitations. The accuracy and the validity of any 
modeling are dependent upon the data used to inform the model. In this simulation, we 
utilize over a decade of the best available patient data from the UNOS database. 
Interdependencies among health and demographic variables are calculated from 10 000s of 
patients. Moreover, discrete event stimulation offers unique strengths over Markov and other 
modeling methods, such as allowing dynamic transitions and making outcomes dependent 
on resource availability. We can also estimate person-specific heterogeneity in risks and 
outcomes.(15) A discrete event simulation can run retrospectively as well. We used this 
strategy to validate our model by comparing withheld data from 2014 and demonstrating 
that our model predicted most variables to within 1–2% of the actual values. Although some 
estimations do fall outside the 95% confidence interval, the absolute differences are small.
Additionally, we utilized alternate scenario analyses to account for potential changes in the 
waitlist. Unknowns such as donor availability and transplant volume could shift in an 
‘optimistic’ direction due to an influx of victims of the opioid epidemic, or trend 
‘pessimistically’ if clinical practices such as poor DCD utilization go unchanged.(6) New 
waitlist additions will be influences by widespread application of HCV therapy and the 
success (or failure) of pharmacologic interventions for NAFLD. Finally, patient level 
characteristics, like disease etiology, MELD score, or age and ethnicity of listed patients 
were altered to give a plausible range of optimistic and pessimistic outcomes.
In sum, based upon best available national data and well-established simulation modeling 
techniques, patients on the liver transplant waitlist will become older, wait longer, receive a 
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transplant at a higher MELD score, and have a greater risk for waitlist drop out. Different 
regions will experience these changes to different degrees, which may lead to increased 
regional and demographic disparities in access to transplant and outcomes posttransplant. 
These epidemiologic changes in listed patients, their risk of drop out, increased overall cost, 
and risk of poorer posttransplant outcome must be considered when determining organ 
allocation in the decade to come. Our discrete events simulation modeling offers a clearer 
more accurate characterization of these changes in the long term.
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UNOS United Network of Organ Sharing
LT Liver Transplantation
NAFLD Non Alcoholic Fatty Liver Disease
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Figure 1. 
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Figure 2. 
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Table 2
Scenario descriptions.
A. Liver Availability B. Patient Arrival C. Patient Attributes
Baseline Scenario Stagnant after 2014 Increase 3% after 2014 Stagnant after 2020
Optimistic Scenario Increase 2% after 2014 Stagnant after 2014 Stagnant after 2014
Pessimistic Scenario Decrease 2% after 2014 Increase 5% after 2014 Stagnant after 2020
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